<p>Esperion Therapeutics Inc. has granted John Harlow, the newly appointed Chief Commercial Officer, non-qualified stock options to purchase 380,000 shares of common stock at an exercise price of $3.79 per share, and 424,536 restricted stock units (RSUs). The options and RSUs will vest 25 percent on the one-year anniversary of the vesting commencement date, with the remaining 75 percent vesting in twelve equal quarterly installments thereafter, contingent on continued employment. These grants were made under the company’s 2017 Inducement Equity Incentive Plan. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Esperion Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9599399-en) on December 09, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

ESPR

<p>Esperion Therapeutics Inc. has granted stock options and RSUs to John Harlow, the new Chief Commercial Officer, under the 2017 Inducement Equity Incentive Plan. The stock options allow the purchase of 380,000 shares at $3.79 per share, and 424,536 RSUs. Vesting occurs over four years, contingent on employment.</p>

Esperion Therapeutics Grants Stock Options and RSUs to New Chief Commercial Officer